242 related articles for article (PubMed ID: 21031518)
1. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
Partridge SC; Vanantwerp RK; Doot RK; Chai X; Kurland BF; Eby PR; Specht JM; Dunnwald LK; Schubert EK; Lehman CD; Mankoff DA
J Magn Reson Imaging; 2010 Nov; 32(5):1124-31. PubMed ID: 21031518
[TBL] [Abstract][Full Text] [Related]
2. Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer.
Kazerouni AS; Peterson LM; Jenkins I; Novakova-Jiresova A; Linden HM; Gralow JR; Hockenbery DM; Mankoff DA; Porter PL; Partridge SC; Specht JM
Breast Cancer Res; 2023 Nov; 25(1):138. PubMed ID: 37946201
[TBL] [Abstract][Full Text] [Related]
3. Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer.
Eby PR; Partridge SC; White SW; Doot RK; Dunnwald LK; Schubert EK; Kurland BF; Lehman CD; Mankoff DA
Acad Radiol; 2008 Oct; 15(10):1246-54. PubMed ID: 18790395
[TBL] [Abstract][Full Text] [Related]
4. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
[TBL] [Abstract][Full Text] [Related]
5.
Diwanji D; Onishi N; Hathi DK; Lawhn-Heath C; Kornak J; Li W; Guo R; Molina-Vega J; Seo Y; Flavell RR; Heditsian D; Brain S; Esserman LJ; Joe BN; Hylton NM; Jones EF; Ray KM
Radiol Imaging Cancer; 2024 Mar; 6(2):e230082. PubMed ID: 38551406
[TBL] [Abstract][Full Text] [Related]
6. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.
Dunnwald LK; Doot RK; Specht JM; Gralow JR; Ellis GK; Livingston RB; Linden HM; Gadi VK; Kurland BF; Schubert EK; Muzi M; Mankoff DA
Clin Cancer Res; 2011 Apr; 17(8):2400-9. PubMed ID: 21364034
[TBL] [Abstract][Full Text] [Related]
7. Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET.
Jansen JF; Schöder H; Lee NY; Stambuk HE; Wang Y; Fury MG; Patel SG; Pfister DG; Shah JP; Koutcher JA; Shukla-Dave A
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):299-307. PubMed ID: 21236594
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
[TBL] [Abstract][Full Text] [Related]
9. Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration.
Semple SI; Staff RT; Heys SD; Redpath TW; Welch AE; Ahearn TS; Hutcheon A; Gilbert FJ
Ann Oncol; 2006 Sep; 17(9):1393-8. PubMed ID: 16788001
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI.
Kim YI; Yoon HJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kim EE; Moon WK; Kang KW
Clin Nucl Med; 2016 Aug; 41(8):614-20. PubMed ID: 27276207
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy.
Tseng J; Dunnwald LK; Schubert EK; Link JM; Minoshima S; Muzi M; Mankoff DA
J Nucl Med; 2004 Nov; 45(11):1829-37. PubMed ID: 15534051
[TBL] [Abstract][Full Text] [Related]
13. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.
Jacobs MA; Ouwerkerk R; Wolff AC; Gabrielson E; Warzecha H; Jeter S; Bluemke DA; Wahl R; Stearns V
Breast Cancer Res Treat; 2011 Jul; 128(1):119-26. PubMed ID: 21455671
[TBL] [Abstract][Full Text] [Related]
15. Integrated
Cho N; Im SA; Cheon GJ; Park IA; Lee KH; Kim TY; Kim YS; Kwon BR; Lee JM; Suh HY; Suh KJ
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):328-339. PubMed ID: 29101445
[TBL] [Abstract][Full Text] [Related]
16. DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study.
Craciunescu OI; Blackwell KL; Jones EL; Macfall JR; Yu D; Vujaskovic Z; Wong TZ; Liotcheva V; Rosen EL; Prosnitz LR; Samulski TV; Dewhirst MW
Int J Hyperthermia; 2009; 25(6):405-15. PubMed ID: 19657852
[TBL] [Abstract][Full Text] [Related]
17. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline
Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649
[TBL] [Abstract][Full Text] [Related]
18. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.
Humbert O; Riedinger JM; Vrigneaud JM; Kanoun S; Dygai-Cochet I; Berriolo-Riedinger A; Toubeau M; Depardon E; Lassere M; Tisserand S; Fumoleau P; Brunotte F; Cochet A
J Nucl Med; 2016 Nov; 57(11):1707-1712. PubMed ID: 27103025
[TBL] [Abstract][Full Text] [Related]
20. Can combined 18F-FDG-PET and dynamic contrast-enhanced MRI predict behavior of desmoid tumors in patients with familial adenomatous polyposis?
Bhandari S; Taylor NJ; Sinha A; Sonoda L; Sanghera B; Wong WL; Goh V; Clark SK
Dis Colon Rectum; 2012 Oct; 55(10):1032-7. PubMed ID: 22965401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]